Nmda Receptor Antagonists in the Medical Intervention of Metabolic Disorders

• US 20080194698A1
• Filed: 02/27/2006
• Published: 08/14/2008
• Est. Priority Date: 03/07/2005
• Status: Abandoned Application

• Current Assignee: Jesus Angel Fernandez-Tresguerres, Michael Hermanussen
• Original Assignee: Jesus Angel Fernandez-Tresguerres, Michael Hermanussen
• Inventors: Hermanussen, Michael, Fernandez-Tresguerres, Jesus Angel
• Application Number:
  US11/885,696
• Publication Number:
  US 20080194698A1
• Time in Patent Office: Days
• US Class Current: 514/662
• CPC Class Codes: A61K 31/13 Amines A61K31/04 takes precedence
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/404 Indoles, e.g. pindolol
• CPC Class Codes: A61K 31/435 having six-membered rings with one nitrogen as the only ring hetero atom
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

The present invention provides for the use of an NMDA receptor antagonist, preferably memantine or neramexane or a pharmaceutical acceptable salt or a prodrug of said antagonists, in the preparation of a pharmaceutical composition for the prevention, amelioration and/or treatment of disorders of metabolism influencing body weight, in particular obesity, an eating disorder and/or in the regulation of appetite. Furthermore, the present invention provides for a method for the prevention, amelioration and/or treatment of disorders of metabolism influencing body weight, in particular obesity, an eating disorder and/or in the regulation of appetite comprising the step of administering to a subject in need thereof a therapeutically effective amount of an NMDA receptor antagonist, preferably memantine or neramexane or a pharmaceutically acceptable salt or prodrug of said antagonists.

Claims

1. (canceled)

2. A method for the prevention, amelioration and/or treatment of disorders of metabolism influencing body weight, an eating disorder and/or in the regulation of appetite comprising the step of administering a therapeutically effective amount of an N-methyl D-aspartate receptor antagonist (NMDA receptor antagonist) or a pharmaceutically acceptable salt or prodrug thereof.

3. The method of claim 2, wherein said NMDA receptor antagonist is selected from the group consisting of memantine or a pharmaceutically acceptable salt or a prodrug thereof, neramexane or a pharmaceutically acceptable salt or a prodrug thereof, MRZ 2/579 or a pharmaceutically acceptable salt or a prodrug thereof, selfotel or a pharmaceutically acceptable salt or a prodrug thereof, aptiganel or a pharmaceutically acceptable salt or a prodrug thereof, licostinel or a pharmaceutically acceptable salt or a prodrug thereof, ACEA 1021 or a pharmaceutically acceptable salt or a prodrug thereof, gavestinel or a pharmaceutically acceptable salt or a prodrug thereof, eliprodil or a pharmaceutically acceptable salt or a prodrug thereof, CP-101606 or a pharmaceutically acceptable salt or a prodrug thereof, and Co101244 or a pharmaceutically acceptable salt or a prodrug thereof.

4. The method of claim 3, wherein said NMDA receptor antagonist is selected from the group consisting of memantine or a pharmaceutically acceptable salt or a prodrug thereof, neramexane or a pharmaceutically acceptable salt or a prodrug thereof, MRZ 2/579 or a pharmaceutically acceptable salt or a prodrug thereof, ACEA 1021 or a pharmaceutically acceptable salt or a prodrug thereof, CP-101606 or a pharmaceutically acceptable salt or a prodrug thereof, Co101244 or a pharmaceutically acceptable salt or a prodrug thereof and eliprodil or a pharmaceutically acceptable salt or a prodrug thereof.

5. The method of claim 4, wherein said NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt or a prodrug thereof.

6. The method of claim 4, wherein said NMDA receptor antagonist is neramexane or a pharmaceutically acceptable salt or prodrug thereof.

7. The method of claim 2, wherein said pharmaceutically acceptable salt is hydrochloride.

8. The method of claim 2, wherein said pharmaceutically acceptable salt is mesylate.

9. The method of claim 2, wherein said disorder of metabolism is a disease related to or involving higher levels of triglycerides.

10. The method of claim 2, wherein said disorder of metabolism is obesity.

11. The method of claim 10, whereby said obesity is overweight.

12. The method of claim 11, wherein said overweight is defined as a body mass index (BMI) between 25 to 30 kg/m² of the subject to be treated.

13. The method of claim 10, wherein said obesity is adipositas.

14. The method of claim 13, wherein said adipositas is defined as a body mass index (BMI) of higher than 30 kg/m² of the subject to be treated.

15. The method of claim 10, wherein said obesity is characterized as 20% or more extra body fat in the subject to be treated.

16. The method of claim 2, wherein said regulation of appetite is the suppression and/or depression of appetite.

17. A method for the prevention of secondary disorders of a disorder related to obesity or a secondary disorder related to increased body weight comprising the step of administering a therapeutically effective amount of an N-methyl D-aspartate receptor antagonist (NMDA receptor antagonist) or a pharmaceutically acceptable salt or prodrug thereof.

18. The method of claim 17, wherein said secondary disorder is selected from the group consisting of diabetes type 2, high blood pressure (hypertension), cardiovascular diseases, cancer, problems with sexual function and disorder of the muscular or bone system.